妊娠期细小病毒B19感染围产结局的系统综述与Meta分析
胎儿感染时宫内死亡率为38.7%,母体感染时为7.3%,宫内输血在胎儿感染中实施率为34.9%。2023-2024年新发波次与既往波次相比,宫内死亡率和胎儿贫血超声征象无显著差异。
要点
- 胎儿感染细小病毒B19时宫内死亡率达38.7%,母体感染时为7.3%。
- 胎儿感染中34.9%接受宫内输血,胎儿水肿发生率为58.7%。
- 2023-2024年新发波次的宫内死亡率与既往波次无显著差异。
核心结论
- 妊娠期细小病毒B19感染与较高的围产期发病率和死亡率相关。
- 2023-2024年新发波次与既往波次相比,宫内死亡率无显著差异。
- 胎儿感染时宫内死亡率远高于仅母体感染的情况。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Scopus、Web of Science、Cochrane Library和CINAHL数据库,时间范围为2000年至2025年4月。
- 总研究人群为3221例母体感染和748例胎儿感染。
主要发现
- 胎儿感染中宫内死亡率为38.7%(95%CI 27.3-51.6),母体感染中为7.3%(95%CI 4.6-11.3)。
- 宫内输血实施率在胎儿感染中为34.9%(95%CI 21.9-50.7),在母体感染中为15.3%(95%CI 7.9-27.6)。
- 胎儿贫血超声征象中,水肿为58.7%(95%CI 38.8-76.2),心脏扩大为39.0%(95%CI 26.3-53.4)。
- 肝受累为10.8%(95%CI 6.1-18.4),胎儿生长受限为9.5%(95%CI 5.0-17.2)。
- 接受产前磁共振成像的胎儿中,异常神经影像率为28.6%(95%CI 17.0-43.9)。
关键数值与推荐
- 新发波次与既往波次胎儿贫血超声征象比较:比值比1.13,95%CI 0.82-1.56,P=0.46。
临床怎么用
- 可根据母体感染或胎儿感染状态向患者告知不同的不良结局发生率。
- 母体感染时宫内死亡率远低于确诊胎儿感染的情况。
- 宫内输血病例产前MRI异常脑发现率较高,可考虑加用二级影像学方法改善产前诊断。
局限性
- 需要大型多中心研究评估产前治疗干预的影响及产前神经影像在宫内输血病例中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The main aim of this study was to evaluate fetal and perinatal outcomes of Parvovirus B19 infection in pregnancy, focusing on the differences between characteristics of the recent disease outbreak (2023-2024) compared to the previous waves. The results should inform clinical management strategies by providing an updated and comprehensive assessment of the literature. DATA SOURCES: MEDLINE, Embase, Scopus, Web of Science, Cochrane Library, and CINAHL databases, from 2000 to April 2025. STUDY ELIGIBILITY CRITERIA: Studies including cases of maternal and/or fetal Parvovirus B19 infection, reporting perinatal outcomes, were included. SYNTHESIS METHOD: We performed a meta-analysis of pooled proportions using a random-effects model; for dichotomous outcomes, logit-transformed proportions were analyzed using generalized linear mixed models. For continuous outcomes (cumulative mean values), random-effects models of mean differences were applied. All outcomes were described in the study cohort, and a second analysis comparing cases from the most recent wave (2023-2024) and older cases was also performed by random-effects meta-regression analysis. RESULTS: Forty-four studies were included in the final analysis, and the total study population encompassed 3221 women and 748 fetuses with Parvovirus B19 infection. The rate of intrauterine demise among fetal infections was 38.7% (95% confidence interval, 27.3-51.6), whereas among maternal infections it was lower (7.3%; 95% confidence interval, 4.6-11.3). Intrauterine transfusion was performed in 34.9% of cases (95% confidence interval, 21.9-50.7) of fetal infections and in 15.3% of cases of maternal infection (95% confidence interval, 7.9-27.6). Ultrasound signs of anemia among infected fetuses included hydrops (58.7%; 95% confidence interval, 38.8-76.2), cardiomegaly (39.0%; 95% confidence interval, 26.3-53.4), hepatic involvement (10.8%; 95% confidence interval, 6.1-18.4), and fetal growth restriction (9.5%; 95% confidence interval, 5.0-17.2). The rate of abnormal neuroimaging was high among fetuses that had prenatal magnetic resonance imaging (28.6%; 95% confidence interval, 17.0-43.9). No significant difference was observed in the rate of intrauterine demise (odds ratio, 0.84; 95% confidence interval, 0.46-1.54; P=.58) or ultrasound signs of fetal anemia (odds ratio, 1.13; 95% confidence interval, 0.82-1.56; P=.46) between the new and the previous waves. The rate of intrauterine transfusions was higher in the recent wave; however, statistical significance was not reached (odds ratio, 1.74; 95% confidence interval, 0.90-3.34; P=.09). CONCLUSION: Parvovirus B19 infection in pregnancy is associated with high perinatal morbidity and mortality. Nevertheless, no significant differences were observed in the rate of intrauterine demise during the recent outbreak of the disease (2023-2024) compared to the previous waves. In clinical practice, findings from this systematic review can inform patients about the rate of adverse outcomes, depending on their status (maternal or fetal infection or fetal infection requiring intrauterine transfusion). In cases of maternal infection, the rate of intrauterine demise is much lower than that in the case of confirmed fetal infection. Finally, the high rate of abnormal brain findings when fetal magnetic resonance imaging was performed in cases of intrauterine transfusion may be relevant to clinicians as reflecting the potential role of adding this second-level imaging method to improve prenatal diagnosis of these cases. Large multicenter studies are needed to evaluate the impact of prenatal therapeutic interventions and the role of prenatal neuroimaging in these cases.
引用
- Sorrenti, Deuster, D'Antonio, et al. Parvovirus B19 infection in pregnancy: perinatal outcomes derived from a systematic review and meta-analysis. Am J Obstet Gynecol. 2026. PMID: 41819197. doi:10.1016/j.ajog.2026.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。